Advanced

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma

Vanderstichele, H; Van Kerschaver, E; Hesse, C; Davidsson, P; Buyse, M A; Andreasen, N; Minthon, Lennart LU ; Wallin, Anders; Blennow, K and Vanmechelen, E (2000) In Amyloid 7(4). p.245-258
Abstract
The standardization and clinical validation of the measurement of beta-amyloid(1-42) (Abeta42) in cerebrospinal fluid (CSF), plasma and urine is described using a commercially available sandwich-type ELISA with 21F12 and 3D6 as monoclonal antibodies. The INNOTEST beta-amyloid(1-42) allows the specific and reliable measurement of(1-42) amyloid peptides in CSF and plasma. The Abeta42 concentrations in serum and urine were below the detection limit. In plasma, no differences were found in Abeta42 levels between controls and patients with different neurodegenerative disorders (Alzheimer's disease (AD), Lewy body disease (LBD), others). In contrast, CSF-Abeta42 concentrations were lower in AD and LBD patients as compared to controls. No... (More)
The standardization and clinical validation of the measurement of beta-amyloid(1-42) (Abeta42) in cerebrospinal fluid (CSF), plasma and urine is described using a commercially available sandwich-type ELISA with 21F12 and 3D6 as monoclonal antibodies. The INNOTEST beta-amyloid(1-42) allows the specific and reliable measurement of(1-42) amyloid peptides in CSF and plasma. The Abeta42 concentrations in serum and urine were below the detection limit. In plasma, no differences were found in Abeta42 levels between controls and patients with different neurodegenerative disorders (Alzheimer's disease (AD), Lewy body disease (LBD), others). In contrast, CSF-Abeta42 concentrations were lower in AD and LBD patients as compared to controls. No correlation was found in AD patients between CSF and plasma concentrations of Abeta42 or between CSF Abeta42 levels and blood-brain-barrier function. The quantitative outcome of the test is in part dependent on confounding factors such as tube type, freeze/thaw cycles, temperature of incubation, standard preparation protocol, and antibody selection. Notwithstanding these aspects, it emerged that Abeta42 is a useful biochemical marker for the diagnosis of AD patients, but there is a need for an international Abeta standard, a universally accepted protocol for CSF preparation, and a thorough evaluation of assay performance in function of the boundary conditions. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Amyloid
volume
7
issue
4
pages
245 - 258
publisher
Parthenon Publishing
external identifiers
  • wos:000165585600002
  • scopus:0033637408
ISSN
1350-6129
DOI
10.3109/13506120009146438
language
English
LU publication?
yes
id
7c899c08-319f-49bd-b500-061bb2bbd751 (old id 1296826)
date added to LUP
2009-07-15 14:55:43
date last changed
2017-10-01 04:34:38
@article{7c899c08-319f-49bd-b500-061bb2bbd751,
  abstract     = {The standardization and clinical validation of the measurement of beta-amyloid(1-42) (Abeta42) in cerebrospinal fluid (CSF), plasma and urine is described using a commercially available sandwich-type ELISA with 21F12 and 3D6 as monoclonal antibodies. The INNOTEST beta-amyloid(1-42) allows the specific and reliable measurement of(1-42) amyloid peptides in CSF and plasma. The Abeta42 concentrations in serum and urine were below the detection limit. In plasma, no differences were found in Abeta42 levels between controls and patients with different neurodegenerative disorders (Alzheimer's disease (AD), Lewy body disease (LBD), others). In contrast, CSF-Abeta42 concentrations were lower in AD and LBD patients as compared to controls. No correlation was found in AD patients between CSF and plasma concentrations of Abeta42 or between CSF Abeta42 levels and blood-brain-barrier function. The quantitative outcome of the test is in part dependent on confounding factors such as tube type, freeze/thaw cycles, temperature of incubation, standard preparation protocol, and antibody selection. Notwithstanding these aspects, it emerged that Abeta42 is a useful biochemical marker for the diagnosis of AD patients, but there is a need for an international Abeta standard, a universally accepted protocol for CSF preparation, and a thorough evaluation of assay performance in function of the boundary conditions.},
  author       = {Vanderstichele, H and Van Kerschaver, E and Hesse, C and Davidsson, P and Buyse, M A and Andreasen, N and Minthon, Lennart and Wallin, Anders and Blennow, K and Vanmechelen, E},
  issn         = {1350-6129},
  language     = {eng},
  number       = {4},
  pages        = {245--258},
  publisher    = {Parthenon Publishing},
  series       = {Amyloid},
  title        = {Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma},
  url          = {http://dx.doi.org/10.3109/13506120009146438},
  volume       = {7},
  year         = {2000},
}